Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
dang1976
dang1976 Jul. 7 at 9:51 PM
$CLRB, insiders bought shares on 3rd of July.
0 · Reply
EvenBetter99
EvenBetter99 Jul. 7 at 7:42 PM
$CLRB Has a top cancer targeting Technology - soon it will be on the market for WM. PDC technology best in class - safe, effective, easy to use. 🚀🚀🚀🚀🚀
0 · Reply
Slab6
Slab6 Jul. 7 at 5:27 PM
$CLRB can it go lower? Please? Seems like it’s stuck here
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 7 at 2:15 PM
$CLRB Much more upside in Radiopharm Theranostics and lower share price. Lantheus bought $5 million worth at $11.70…
0 · Reply
kalbany
kalbany Jul. 7 at 2:07 PM
$CLRB Now I know why people don't trust this company to make the right decision. My stake is very small, so I don't feel bad. I understand why folks don't jump in either.
1 · Reply
Heywood_Jablomi
Heywood_Jablomi Jul. 7 at 1:52 PM
$CLRB well, people clearly aren’t buying the dip here
1 · Reply
EvenBetter99
EvenBetter99 Jul. 6 at 7:51 AM
$CLRB 1 Billion Mct Cap will multiply the share price about 115 times.
0 · Reply
YasirTrades
YasirTrades Jul. 5 at 3:26 AM
GLMD is running out of time in a good way. The 90-day definitive agreement window from April 28th ends this month. You don’t get many biotech plays under $1 with a $12+ book value and real M&A potential. Low float, strong cash, and a clear catalyst. It’s a ticking time bomb in a setup kind of way. $CABA $ALLR $CNTB $CLRB
0 · Reply
Scorpole
Scorpole Jul. 3 at 4:45 PM
$CLRB So that was the purpose with R/S and offering. Just so the management could get cheaper shares
2 · Reply
szcyxzh
szcyxzh Jul. 3 at 4:09 PM
$CLRB Reminder: CEO James Caruso’s total comp in 2023 was over $1 million, including cash salary and stock awards. Other executives received similarly high compensation relative to company revenue (which is $0). They contributed a symbolic amount during dilution, while drawing six- or seven-figure salaries funded by those very dilution rounds. Draw your own conclusion.
0 · Reply
Latest News on CLRB
Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 2 months ago

Cellectar Announces Plan to Explore Strategic Alternatives


Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 4 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript


dang1976
dang1976 Jul. 7 at 9:51 PM
$CLRB, insiders bought shares on 3rd of July.
0 · Reply
EvenBetter99
EvenBetter99 Jul. 7 at 7:42 PM
$CLRB Has a top cancer targeting Technology - soon it will be on the market for WM. PDC technology best in class - safe, effective, easy to use. 🚀🚀🚀🚀🚀
0 · Reply
Slab6
Slab6 Jul. 7 at 5:27 PM
$CLRB can it go lower? Please? Seems like it’s stuck here
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 7 at 2:15 PM
$CLRB Much more upside in Radiopharm Theranostics and lower share price. Lantheus bought $5 million worth at $11.70…
0 · Reply
kalbany
kalbany Jul. 7 at 2:07 PM
$CLRB Now I know why people don't trust this company to make the right decision. My stake is very small, so I don't feel bad. I understand why folks don't jump in either.
1 · Reply
Heywood_Jablomi
Heywood_Jablomi Jul. 7 at 1:52 PM
$CLRB well, people clearly aren’t buying the dip here
1 · Reply
EvenBetter99
EvenBetter99 Jul. 6 at 7:51 AM
$CLRB 1 Billion Mct Cap will multiply the share price about 115 times.
0 · Reply
YasirTrades
YasirTrades Jul. 5 at 3:26 AM
GLMD is running out of time in a good way. The 90-day definitive agreement window from April 28th ends this month. You don’t get many biotech plays under $1 with a $12+ book value and real M&A potential. Low float, strong cash, and a clear catalyst. It’s a ticking time bomb in a setup kind of way. $CABA $ALLR $CNTB $CLRB
0 · Reply
Scorpole
Scorpole Jul. 3 at 4:45 PM
$CLRB So that was the purpose with R/S and offering. Just so the management could get cheaper shares
2 · Reply
szcyxzh
szcyxzh Jul. 3 at 4:09 PM
$CLRB Reminder: CEO James Caruso’s total comp in 2023 was over $1 million, including cash salary and stock awards. Other executives received similarly high compensation relative to company revenue (which is $0). They contributed a symbolic amount during dilution, while drawing six- or seven-figure salaries funded by those very dilution rounds. Draw your own conclusion.
0 · Reply
GeneralVonEssen
GeneralVonEssen Jul. 3 at 3:37 PM
$CLRB wow offering of $4 on public shares? What did they think wpuld happen?
1 · Reply
szcyxzh
szcyxzh Jul. 3 at 3:04 PM
$CLRB The management pay out 50,000 to show supports (crocodile tears), then draws a million dollar paycheck from the raising as a result of the dilution. It is a good business if you can find one.
0 · Reply
Slab6
Slab6 Jul. 3 at 2:45 PM
$CLRB did the short interest really decrease by 95%??
0 · Reply
Pedelco
Pedelco Jul. 3 at 2:43 PM
$CLRB do it like James 💰 and buy
0 · Reply
Slab6
Slab6 Jul. 3 at 2:42 PM
$CLRB market cap of 9 million 😂
0 · Reply
Slab6
Slab6 Jul. 3 at 2:05 PM
$CLRB CEO, CFO, and COO bought at $4.99. Scooped a few here. Looks like price is going to stabilize here moving forward hopefully! 🤞🏻
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 3 at 2:05 PM
$CLRB CEO purchased 10,000 shares at $4.99 for a total of $49,900. CARUSO JAMES V now owns 11,638 shares. https://ceo-buys.com
0 · Reply
Slab6
Slab6 Jul. 3 at 1:39 PM
$CLRB looks like insiders are loading up
1 · Reply
RAGC
RAGC Jul. 3 at 1:17 PM
$CLRB news 👇
1 · Reply
szcyxzh
szcyxzh Jul. 2 at 11:35 PM
$CLRB and the 6-month runway extension is based on assumption that they can timely enroll eligible patients. TRBC is hard to find. And the track record for previous trials from this management is disaster, to put it politely.
1 · Reply
szcyxzh
szcyxzh Jul. 2 at 11:25 PM
$CLRB quarterly burn rate is around $3–4 million, management pay is over 2 million annually. This 150% dilution buys shareholders another 6 months from today at most.
0 · Reply
szcyxzh
szcyxzh Jul. 2 at 11:12 PM
$CLRB What the management will repeat is that: announce positive trial news, draw ppt for a few academic conferences, then say regulation challenges and need more money to run this show, until retirement. no product, no revenue, no honor of words but only care about their paycheck.
0 · Reply